Coya Therapeutics Inc. (COYA)
Coya Therapeutics Statistics
Share Statistics
Coya Therapeutics has 16.72M shares outstanding. The number of shares has increased by 9.88% in one year.
Shares Outstanding | 16.72M |
Shares Change (YoY) | 9.88% |
Shares Change (QoQ) | 0.11% |
Owned by Institutions (%) | n/a |
Shares Floating | 15.55M |
Failed to Deliver (FTD) Shares | 100 |
FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 199.71K, so 1.2% of the outstanding shares have been sold short.
Short Interest | 199.71K |
Short % of Shares Out | 1.2% |
Short % of Float | 1.29% |
Short Ratio (days to cover) | 3.4 |
Valuation Ratios
The PE ratio is -5.87 and the forward PE ratio is -5.38. Coya Therapeutics's PEG ratio is -0.24.
PE Ratio | -5.87 |
Forward PE | -5.38 |
PS Ratio | 0.02 |
Forward PS | 3.5 |
PB Ratio | 0 |
P/FCF Ratio | -0.01 |
PEG Ratio | -0.24 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Coya Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.59, with a Debt / Equity ratio of 0.
Current Ratio | 11.59 |
Quick Ratio | 11.59 |
Debt / Equity | 0 |
Debt / EBITDA | 0 |
Debt / FCF | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $444.26M |
Profits Per Employee | $-1.86M |
Employee Count | 8 |
Asset Turnover | 0.08 |
Inventory Turnover | n/a |
Taxes
Income Tax | 720.29M |
Effective Tax Rate | -5.09% |
Stock Price Statistics
The stock price has increased by -34.91% in the last 52 weeks. The beta is 0.32, so Coya Therapeutics's price volatility has been higher than the market average.
Beta | 0.32 |
52-Week Price Change | -34.91% |
50-Day Moving Average | 6.46 |
200-Day Moving Average | 6.48 |
Relative Strength Index (RSI) | 50.13 |
Average Volume (20 Days) | 91.69K |
Income Statement
In the last 12 months, Coya Therapeutics had revenue of 3.55B and earned -14.88M in profits. Earnings per share was -0.98.
Revenue | 3.55B |
Gross Profit | 3.55B |
Operating Income | -17.25B |
Net Income | -14.88M |
EBITDA | -17.22M |
EBIT | -17.25M |
Earnings Per Share (EPS) | -0.98 |
Balance Sheet
The company has 38.34M in cash and 0 in debt, giving a net cash position of 38.34M.
Cash & Cash Equivalents | 38.34M |
Total Debt | 0 |
Net Cash | 38.34M |
Retained Earnings | -40.74B |
Total Assets | 44.35M |
Working Capital | 40.48M |
Cash Flow
In the last 12 months, operating cash flow was -10.29B and capital expenditures 0, giving a free cash flow of -10.29B.
Operating Cash Flow | -10.29B |
Capital Expenditures | 0 |
Free Cash Flow | -10.29B |
FCF Per Share | -675.17 |
Margins
Gross margin is 100%, with operating and profit margins of -485.35% and -0.42%.
Gross Margin | 100% |
Operating Margin | -485.35% |
Pretax Margin | -398.43% |
Profit Margin | -0.42% |
EBITDA Margin | -0.48% |
EBIT Margin | -485.35% |
FCF Margin | -289.49% |
Dividends & Yields
COYA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for COYA is $18, which is 179.1% higher than the current price. The consensus rating is "Buy".
Price Target | $18 |
Price Target Difference | 179.1% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Scores
Altman Z-Score | 92.28 |
Piotroski F-Score | 4 |